Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, National Hospital for Tropical Diseases, 78 Giai Phong Street, Hanoi, Vietnam.
Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Hospital for Tropical Diseases, 764 Vo Van Kiet Street, Ward 1, District 5, Ho Chi Minh City, Vietnam.
Nat Rev Cardiol. 2014 Jun;11(6):335-45. doi: 10.1038/nrcardio.2014.40. Epub 2014 Apr 8.
Dengue is one of the most important emerging viral diseases globally. The majority of symptomatic infections result in a relatively benign disease course. However, a small proportion of patients develop severe clinical manifestations, including bleeding, organ impairment, and endothelial dysfunction with increased capillary permeability causing hypovolaemic shock that can lead to cardiovascular collapse. Evidence is increasing that dengue can also cause myocardial impairment, arrhythmias and, occasionally, fulminant myocarditis. No antiviral agents or vaccines are licensed for dengue, and treatment remains supportive with judicious fluid replacement for patients with severe disease. Defining the role of cardiac dysfunction in the haemodynamic compromise of severe dengue has potentially important management implications. In this Review, we will outline the current understanding of the cardiovascular manifestations of dengue, including myocardial and vascular involvement, and conclude with a discussion of the available therapeutic options and potential future research directions.
登革热是目前全球最重要的新发病毒性疾病之一。大多数有症状的感染导致相对良性的疾病过程。然而,一小部分患者会出现严重的临床表现,包括出血、器官损伤和内皮功能障碍,增加毛细血管通透性导致低血容量性休克,可导致心血管衰竭。越来越多的证据表明,登革热也可导致心肌损伤、心律失常,偶尔还会导致暴发性心肌炎。目前还没有针对登革热的抗病毒药物或疫苗,对于重症患者,治疗仍然是支持性的,即谨慎地进行液体补充。明确心脏功能障碍在重症登革热血液动力学障碍中的作用具有重要的管理意义。在这篇综述中,我们将概述登革热的心血管表现,包括心肌和血管受累,并讨论现有的治疗选择和潜在的未来研究方向。